Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes. The same molecule is sold under the brand name Wegovy at a higher dose for chronic weight management, and as Rybelsus in oral tablet form for diabetes. The three brand names, same active ingredient, produce very different Medicare coverage outcomes in 2026.
Medicare Part D covers Ozempic when the medical indication is type 2 diabetes. Your plan's formulary and tier placement determine the actual copay. Most plans place Ozempic on tier 3 (preferred brand) or tier 4 (non-preferred brand), resulting in monthly cost sharing between $25 and $150 once the deductible is met. Prior authorization is almost universally required. Without prior authorization or an approved diabetes diagnosis code, the claim will be denied regardless of tier.
The weight-loss exclusion is statutory, not a plan preference. Section 1860D-2(e) of the Social Security Act (as amended by the Medicare Modernization Act of 2003) prohibits Part D plans from covering drugs when the primary indication is weight loss. This is why Wegovy, the higher-dose semaglutide product, has historically been excluded from Medicare, while Ozempic in the same drug class has been covered for diabetes. Starting July 2026, a CMS-run GLP-1 Bridge demonstration pilot will make Wegovy and Zepbound available for weight loss at $50/month, but Ozempic is not part of that pilot.
What Ozempic Medicare Coverage Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same ozempic medicare coverage can cost many times more at a hospital than at your local pharmacy:
2026 Ozempic Medicare Coverage Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, no insurance) | $935 - $1,050/month | Novo Nordisk list price $997.58 per pen (all strengths) |
| Medicare Part D (diabetes indication) | $25 - $150/month | Tier 3-4 copay after deductible; $2,100 annual OOP cap applies |
| Inpatient hospital (Part A) | $935 - $1,500/pen (facility charge) | Bundled under Part A DRG payment; billed at facility rates |
| Medicare (weight loss, no diabetes diagnosis) | Not covered | Federal law (MMA 2003) prohibits Part D coverage for weight loss indication |
| Medicaid | $1 - $4/prescription | Coverage varies by state; prior authorization typically required |
Part D costs depend on plan formulary tier and deductible phase. The 2026 Part D deductible maximum is $615. Retail prices sourced from Novo Nordisk list price (NovoCare.com, 2026).
Source: Novo Nordisk NovoCare list price 2026, CMS Medicare Part D 2026 parameters, CMS.gov
Why Hospitals Charge So Much
When Ozempic is administered during an inpatient hospital stay, the cost is bundled into the hospital's Diagnosis-Related Group (DRG) payment under Medicare Part A rather than billed as a separate pharmacy line item. Hospitals may still list it as a charge on the patient's itemized bill, but the actual Medicare payment to the hospital for an inpatient stay covers all drugs administered, including Ozempic, as part of the global DRG rate.
Outside the hospital, Ozempic is a self-administered drug. Because patients inject it themselves (typically at home, once weekly), it is not billable under Medicare Part B, which covers physician-administered drugs. This is why there is no Medicare Part B ASP rate for Ozempic and why it does not have a unique HCPCS J-code for outpatient infusion billing. The correct billing pathway is always Part D pharmacy benefit, not Part B medical benefit.
Patients who see an Ozempic line item on an outpatient bill coded as a physician-administered drug under Part B should review the claim carefully. Part B coverage would require that a clinician administered the injection in a clinical setting, which is rare for Ozempic. Billing Ozempic as Part B when the patient self-administered it is a common error that results in claim denial and potential overpayment.
Patient Assistance Programs
Novo Nordisk runs a patient assistance program (PAP) for Ozempic for qualifying uninsured patients. Note that as of 2026, Medicare Part D beneficiaries with Ozempic coverage are no longer eligible for the PAP. Uninsured patients and those without Part D coverage may qualify:
Patient assistance programs for Ozempic Medicare Coverage| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novo Nordisk Patient Assistance Program (NovoCare PAP) | Free Ozempic supply if income at or below 200% FPL; uninsured patients only (Medicare Part D holders excluded in 2026) | novocare.com/diabetes/help-with-costs/pap.html |
| Novo Nordisk Savings Offer Card | $199/month for 0.25mg or 0.5mg pen (new self-pay patients through June 2026); not usable with Medicare Part D | ozempic.com/savings-and-resources/save-on-ozempic.html |
| NeedyMeds Drug Database | Directory of all manufacturer and third-party assistance programs for semaglutide products | needymeds.org |
Medicare Part D beneficiaries cannot use manufacturer savings cards under federal Anti-Kickback Statute rules. Medicare patients who cannot afford Ozempic should ask their plan about Extra Help (Low Income Subsidy) enrollment.
Source: NovoCare.com, NeedyMeds.org, Novo Nordisk 2026 PAP terms
Medicare Part D
Medicare Part D covers Ozempic when prescribed for type 2 diabetes. Each plan's formulary determines whether Ozempic is covered and at which tier. Most plans place it on tier 3 (preferred brand) or tier 4 (non-preferred brand). After meeting the plan deductible (up to $615 in 2026), beneficiaries typically pay 25% coinsurance or a flat copay of $25 to $150 per month depending on the plan. Once annual out-of-pocket spending reaches $2,100 in 2026, the plan pays 100% for the rest of the year.
Prior authorization is required by nearly all Medicare Part D plans for Ozempic. The prior authorization process requires your prescribing physician to submit documentation confirming a type 2 diabetes diagnosis and, in many cases, proof that you tried a less expensive diabetes medication first (typically metformin). If prior authorization is denied, you have the right to request an exceptions or appeals review through your plan within 60 days.
For weight loss without a diabetes diagnosis, Ozempic is not covered by Medicare Part D. This prohibition comes from federal statute, not plan design. The July 2026 GLP-1 Bridge pilot program will make Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) available at $50 per month for eligible Medicare beneficiaries with obesity and a qualifying cardiovascular condition. Ozempic is not included in the Bridge pilot because it is not FDA-approved for chronic weight management.
Common Ozempic Medicare Coverage Billing Errors
Ozempic generates a distinct set of billing problems due to the diabetes-versus-weight-loss coverage divide and its status as a self-administered drug. Check for these errors if you receive an unexpected denial or bill:
- Claim submitted under Medicare Part B (physician-administered) when Ozempic was self-injected at home. Ozempic is a self-administered drug and belongs under Part D, not Part B. Part B claims for Ozempic will be denied.
- Wrong diagnosis code on the Part D claim (obesity or weight loss ICD-10 code instead of type 2 diabetes E11.xx). Medicare will deny Part D coverage if the primary diagnosis on file is a weight-management code rather than a diabetes code.
- Manufacturer savings card applied to a Medicare Part D claim. Federal law prohibits Medicare beneficiaries from using manufacturer coupons with Part D. The claim must go through your plan at plan rates.
- Billed as Wegovy (semaglutide 2.4 mg) when the prescription was for Ozempic, or vice versa. The two drugs have different NDC numbers, different FDA approvals, and different Medicare coverage status. A mix-up in the NDC number on the pharmacy claim can cause a denial or result in a payment for the wrong product.
- Prior authorization not obtained or expired before the fill. Without a current prior authorization, the Part D claim will be rejected at the pharmacy counter. Prior authorizations typically expire annually and must be renewed with current clinical documentation.
Frequently Asked Questions
Does Medicare cover Ozempic in 2026?
Yes, but only for type 2 diabetes. Medicare Part D plans cover Ozempic (semaglutide) when it is prescribed to control blood sugar in adults with type 2 diabetes, subject to prior authorization and formulary placement. Medicare does not cover Ozempic for weight loss under current federal law. Most Part D beneficiaries with a diabetes diagnosis pay $25 to $150 per month for Ozempic after the plan deductible.
Why won't Medicare cover Ozempic for weight loss?
Federal law, specifically Section 1860D-2(e) of the Social Security Act added by the Medicare Modernization Act of 2003, prohibits Medicare Part D from covering any drug prescribed primarily for weight loss. This statutory ban was written before GLP-1 drugs existed. A new CMS GLP-1 Bridge pilot starting July 2026 will cover Wegovy and Zepbound for weight loss at $50/month, but Ozempic is not included because it is not FDA-approved for chronic weight management.
How much does Ozempic cost with Medicare Part D in 2026?
With Medicare Part D, Ozempic typically costs $25 to $150 per month after meeting the plan deductible (maximum $615 in 2026). Ozempic is placed on tier 3 or tier 4 by most plans, meaning 25% coinsurance or a non-preferred brand copay. Once you spend $2,100 out of pocket on covered Part D drugs in 2026, your plan covers 100% of further drug costs for the rest of the year.
What is the retail price of Ozempic without insurance in 2026?
Without insurance, Ozempic lists at $997.58 per pen (all strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg), or roughly $935 to $1,050 per month depending on the pharmacy. The Novo Nordisk savings offer for new self-pay patients priced at $199/month for the starter dose (0.25 mg or 0.5 mg) was available through June 2026. GoodRx and discount programs can reduce retail cost but typically not below the $800 range at most pharmacies.
Can I get Ozempic through the Novo Nordisk patient assistance program if I have Medicare?
Generally no, as of 2026. Novo Nordisk changed PAP eligibility in 2026 to exclude most Medicare Part D beneficiaries with Ozempic coverage. The program states that 98% of Medicare Part D plans now cover Ozempic for diabetes, so Medicare enrollees are directed to use their Part D benefit. Uninsured patients who meet the income threshold (at or below 200% of the federal poverty level) may still apply through NovoCare.com.
Does Medicare cover Wegovy or Rybelsus in 2026?
Wegovy (semaglutide 2.4 mg) for weight loss has been excluded from Medicare Part D under the same statutory ban as Ozempic, but the July 2026 GLP-1 Bridge pilot will cover Wegovy at a $50/month copay for eligible Medicare beneficiaries with obesity and qualifying cardiovascular conditions. Rybelsus (oral semaglutide for diabetes) is covered by Part D plans that list it on their formulary, similar to Ozempic.
What happens if my Medicare Part D prior authorization for Ozempic is denied?
You have several options. First, ask your doctor to submit additional clinical documentation supporting the diabetes diagnosis. Second, request a coverage exception with your plan, which requires your doctor to explain why Ozempic is medically necessary versus a less expensive alternative. Third, file a formal appeal within 60 days of the denial. If you need Ozempic urgently, ask about an expedited appeal, which the plan must process within 72 hours.
Is Ozempic covered by Medicaid in 2026?
Medicaid coverage of Ozempic varies by state. Most state Medicaid programs cover GLP-1 drugs for diabetes with prior authorization, and copays are typically $1 to $4 per prescription. Some states have added GLP-1 obesity coverage following IRA-era policy changes. Check with your state Medicaid agency or use the CoveredUSA Medicaid income limits tool to confirm eligibility and coverage in your state.
